The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer

Eligibility Criteria

• * Age ≥18 years
• * Patients meeting one of the following criteria:
• * Tumor clinical stage T3a or higher
• * Gleason score 8-10, or
• * PSA level \> 20 ng/mL
• * Patients deemed fit for surgery on the basis of preoperative evaluation at the physician's discretion
• * Patient is scheduled for standard of care laparoscopic radical prostatectomy (with or without robotic assistance) Salvage PLND
• * Age ≥18 years
• * Patients with presence of suspicious lymph node on CT or MRI (of a pelvic node =\> 10mm in short axis or a node with abnormal morphology such as roundness irregularity or loss of fatty hilum, or PSMA-avid on PSMA PET imaging
• * Patients deemed fit for surgery on the basis of preoperative evaluation at the physician's discretion
• * Patient is scheduled for standard of care salvage pelvic lymph node dissection (with or without robotic assistance)
• * Contraindications to standard-of-care MR imaging (e.g., metal implants, claustrophobia)
• * Prior androgen-deprivation therapy for prostate cancer (N/A for Salvage PLND)
• * Prior pelvic radiotherapy (N/A for Salvage PLND )
• * Medical illness unrelated to the tumor that, in the opinion of the attending physician and principal investigator, will preclude administration of the tracer
• * Weight greater than the 400-lb weight limit of the PET scanner
• * Unmanageable claustrophobia
• * Inability to lie in the scanner for 30 min